We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.33 | 3.70% | 9.25 | 9.00 | 9.50 | 9.30 | 9.25 | 9.30 | 180,216 | 09:12:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 5.27M | -11.94M | -0.0129 | -7.17 | 85.82M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/2/2019 08:28 | I remember seeing BB comments that Modi will function without CI ? What are you getting at ? Thanks. | torquayfan | |
18/2/2019 08:15 | TF - yes it is and it was a genuine and important question. | bermudashorts | |
18/2/2019 08:11 | Bermuda - I'm just glad to see THE man enthusing about vaccines. I thought it was a very interesting link. | torquayfan | |
18/2/2019 07:44 | TF Thanks for that - so are we now suggesting that Moditope will also be a combination therapy? | bermudashorts | |
17/2/2019 16:37 | Come on now, don't be shy, say what you mean! | 10acious | |
17/2/2019 15:43 | Don't forget the SCIB1 mouse model is proven ... LOL | inanaco | |
17/2/2019 15:21 | 10acious Of course the field is so crowded because the rewards are so high. In the interest of balance this is from Scancell:- 'results demonstrate that it might be possible to rescue a poor vaccine and/or a non-responsive anti-PD-1 tumor by using a combination but then the survival is still very low. In contrast, our vaccine alone gives good survival and anti-PD-1 alone shows therapeutic efficacy in 50% of the animals (similar to results in melanoma patients) but the combination gives an overall survival of 80%.' | bermudashorts | |
17/2/2019 14:10 | Thank you for that, very much an eye opener for me.What a crowded field,that has it seems,developed into nothing more than a dash for the cash. Easy now to see why progress for Scancell appears to be so slow.With the competition so vast the resources so relatively limited and failure rates as high as they are I'm happy to leave this in the... small speculative punt...bottom draw!As David Berman, who runs immuno-oncology at AstraZeneca, puts it bluntly: "Everything works in mice." And while animal models have improved in recent years, "they aren't as helpful as they were in other types of therapy-and even there, it's questionable how much predictiveness they have," adds Joanne Lager, who leads oncology development at Sanofi.Liked that bit of reality. | 10acious | |
17/2/2019 12:00 | Why is the market cap a whopping 24m? | kreature | |
17/2/2019 11:38 | 10acious thanks for that - below is link to an article posted a few months ago now. It's the best article on combination studies that I've read - not too detailed or technical and gives a good basic outline of the issues. It's a long article but would strongly recommend that any holders here have a read. Re. your comment on patient nos. the article only includes figures up to 2017 but during the last 18 months there has been an explosion in the number of combination studies - depending on what article you read there are now between 1500 and 2500 trials. According to the Cancer Research Institute the figure is 2250 which involves the need to recruit over 380,000 patients. In some cancers there simply aren't enough patients to fill the trials. The fact that Scancell have signed up major cancer centres in the US for the SCIB1 trial should very much help with recruitment for SCIB1 (assuming there's no change from previous announcements). When it comes to SCIB2, CRUK have a network of dedicated clinical trial centres. | bermudashorts | |
17/2/2019 09:27 | Scancell have attended more meetings and presentations than Donald Trump. It makes no difference to a positive outlook, indeed, it has a negative impact on the share price because they continue to burn money without income. They have lost their way | terror | |
17/2/2019 08:28 | Immunotherapies could change kidney cancer care, studies suggesthttps://www.c | 10acious | |
16/2/2019 13:14 | Dr - yes exactly, it's an investment conference so assume CH will be attending. Let's hope he needs to update his pitch with some progress on both platforms. | bermudashorts | |
16/2/2019 12:00 | Looks like Scancell are attending Biotrinity in London in April. | bermudashorts | |
16/2/2019 02:12 | Gazza. Thanks for the reply. Nice weekend to you. | torquayfan | |
15/2/2019 15:48 | 19797 - So YOU call this LOSS making EGO trip of YOURs....LIFE do YOU ??? Sane people might call it = ' An Affliction' | the real lozan | |
15/2/2019 15:10 | Tosh yet again decapitated ... life goes on for the rest of us | inanaco | |
15/2/2019 14:39 | except the SCIB1 tests results did transfer from mouse to Human ... oh dear !! | inanaco | |
15/2/2019 14:29 | Like i said, jog on... nothing you post is of any relevance . anyone can cut and paste, and what your post has got to do with the fact that you've finally accepted that our " platforms " are NOT PROVEN, and do contain RISK, is a mystery. Test results in mice do not always transfer to the same results in humans... FACT. Now jog on theres a good lad. | tosh123 | |
15/2/2019 14:18 | Just so you know the difference between Jerry ...and a medical mouse as currently developed Tosh .. A humanized mouse is a mouse carrying functioning human genes, cells, tissues, and/or organs. Humanized mice are commonly used as small animal models in biological and medical research for human therapeutics. Immunodeficient mice are often used as recipients for human cells or tissues, because they can relatively easily accept heterologous cells due to lack of host immunity. Traditionally, the nude mouse and severe combined immunodeficiency (SCID) mouse have been used for this purpose, but recently the NCG mouse, NOG mouse[1] and the NSG mouse[2] have been shown to engraft human cells and tissues more efficiently than other models.[3][4][5] Two mouse strains, called MITRG and MISTRG, were described in which human versions of four genes encoding cytokines important for innate immune cell development are knocked into their respective mouse loci. Such humanized mouse models may be used to model the human immune system in scenarios of health and pathology, and may enable evaluation of therapeutic candidates in an in vivo setting relevant to human physiology.[6] search Wiki ... for explanations of Humanised Mouse and you can form an argument with the industry rather than me | inanaco | |
15/2/2019 14:08 | you are a tough guy ... i forgot ! | inanaco | |
15/2/2019 14:06 | and i suggest that you jog on. Nothing you have to say is of any relevance. | tosh123 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions